Member Info for Hurst10

More M&A pre ASCO
It’s the rare triple down: Bristol Myers Squibb is once again revising a massive research collaboration with immunotherapy drug discovery biotech Immatics. BMS is adding new deal with $60 million upfront and $700 million down the line for at least two new programs, plus expanding its prior arrangement.
That brings the total value of the collaborations to $4.2 billion in biobucks. The deal was originally signed in 2019 by Celgene before it was absorbed into BMS, and BMS again inked an agreement with Immatics in 2021.

Avacta will be there, like they were at AACR
All the majors wants to talk to them

Usual suspects on the bid
U.K. Market closed on Friday while ASCO open !!!
LG etc will all be at ASCO

Yes buyers taking over and plenty of bulk buying taking over, testing the offer price.
With two bank holidays and LG pharma, PointBio pharma etc attending ASCO( kicking off Friday with Precision Medicine panel discussion) management from Avacta attending will certainly have follow up meetings from AACR presentation.
Long week end ahead, rest of the world working, so we could have news flow early next week. 128-30 at close, but I would not miss out!!!

Stand by for the other side of the sales prints this morning,popping up around noon and all afternoon.
Pre ASCO and upcoming news.
128-30 by close and two days closed while ASCO starts on Friday.

And perhaps the PR chaps should amend Google translate, so we have the name Affyxell instead !!!

Note now 4 on the bid while only one offering stock
125-30 around the corner

First two hours and over 1 mill traded, plenty of 25/ going through and the usual on bid.
130-5 before 12.00

From MarketWatch:
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week?s American Society of Clinical Oncology annual meeting

Index funds buying, did not qualify before

Have never suggested Avacta will be discussed at the particular panel discussion.
Precision medicine is the subject.
From Avacta’s annual report :
Avacta Group plc (AIM: AVCT), a clinical stage oncology company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces it will present a poster entitled ‘AVA6000, a novel precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage’, at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

What we need to remember is that on that very first day of ASCO the 3rd of June, there will be a panel of discussion on Precision Medicine,hence the timing of AVA6000 and the latest
Publication of key AVA6000 pre-clinical data at American Association of Cancer Research (AACR) New Orleans Convention Center, 11-13th April 2022, will be picked up again at ASCO.
:
First patient dosed on 11th August 2021 at The Royal Marsden.
• Dose escalated February 2022 to 120 mg/m2 in ongoing second cohort.
• US IND approved by FDA in November 2021:
• Two US clinical trial sites being initiated and should contribute to the dose escalation phase in Q2.
What we could expect is a further escalation of the cohort and the dose escalated to 160mg/m2.
The timing of the news flow is perfect and we will have majors lining up !
Not to mentioned further interest from the US buy side.
Will be an amazing June!

Sure we will see the stock back at 130p and above with ASCO coming up and Precision medicine panel discussion on day 1 on 3/6.
Every buy side fund will be there and news flow from the sector will be very active.

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2 - LifeArc

With Point Biopharma out with Q1 and the company presenting at Guggenheim on the 17/5 and at UBS on 24/5 and then we have ASCO commencing on 3/6, with a panel discussion on opening day:
Precision Medicine in Colorectal Cancer: A Decade of Progress and Future Directions
Primary Track: Gastrointestinal Cancer—Colorectal and Anal
Presentations
Microsatellite Instability Colorectal Cancer: Known Knowns, Unknown Knowns, and Unknown Unknowns
Chair: Mohamed E. Salem, MD | Levine Cancer Institute, Atrium Health
Targeting the BRAF Mutation in Colorectal Cancer: Clinical and Molecular Insights
Speaker: Josep Tabernero, MD, PhD | Vall d’Hebron Institute of Oncology
HER2 in Colorectal Cancer: Are We There Yet?
Speaker: Sara Lonardi, MD | Veneto Institute of Oncology, IRCCS
Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

Volume picking up.
Good morning NY

12 x 500 trades in the last 10 min

Upcoming milestone payments all USD

With Avacta being a strong USD earner, worth looking at the continued strength of the USD vs GBP in the current markets.